Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer

Despite recent improvements to current therapies and the emergence of novel agents to manage advanced non-small cell lung cancer (NSCLC), the patients' overall survival remains poor. Re-challenging with first-line chemotherapy upon relapse is common in the management of small cell lung cancer b...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Khurum, Hanna, Gerard G, Campbell, Lynn, Scullin, Paula, Hussain, Adnan, Eakin, Ruth L, McAleese, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sun Yat-sen University Cancer Center 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845541/
https://www.ncbi.nlm.nih.gov/pubmed/23981850
http://dx.doi.org/10.5732/cjc.013.10120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845541/
https://www.ncbi.nlm.nih.gov/pubmed/23981850
http://dx.doi.org/10.5732/cjc.013.10120

Ejemplares similares